Diagnostics and Research Tools

Source inventory

This note uses the following source categories, ordered by evidentiary strength:

The two core technical papers are peer-reviewed journal articles, not preprints. The patent cited is a granted patent, not an application. This matters because only peer-reviewed papers and granted patents support moat/feasibility claims under the source-tier rules [S1][S2][S3].

What the Tier 1 evidence actually shows

2.1 CRISPR-Cas13/collateral-cleavage detection

Gootenberg et al. published “Nucleic acid detection with CRISPR-Cas13a/C2c2” in Science in 2017 [S1]. The paper reports a platform called SHERLOCK that uses Cas13a’s RNA-guided RNA-targeting activity and its non-specific, “collateral” cleavage of nearby reporter RNA after target recognition. The team showed detection of Zika and Dengue viral RNA, discrimination of pathogenic bacteria, human genotyping, and identification of cell-free tumor DNA mutations. The paper states sensitivity down to attomolar concentrations in laboratory demonstrations [S1]. The work is Tier 1 because it is a DOI-verified peer-reviewed paper: DOI 10.1126/science.aam9321.

2.2 CRISPR-Cas12/double-stranded DNA detection

Chen et al. published “CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity” in Science in 2018 [S2]. This paper is independently produced by a different institution (University of California, Berkeley, among others) from the Broad Institute-led Gootenberg paper. It reports that Cas12a, after binding a target double-stranded DNA, performs indiscriminate single-stranded DNA cleavage. This principle enables DETECTR-type DNA assays. The paper is Tier 1, DOI 10.1126/science.aar6245.

Load-bearing technical claim: CRISPR-Cas effector enzymes can be repurposed for sequence-specific nucleic acid detection through target-triggered collateral cleavage of reporters. This is cross-verified by two independent institutions: Broad/MIT lineage [S1] and UC Berkeley lineage [S2]. No [SINGLE-SOURCE] tag is required for this specific claim.

2.3 What the granted patent does and does not prove

US8697359B2, “CRISPR-Cas systems and methods for altering expression of gene products,” was granted April 15, 2014, to the Broad Institute and MIT [S3]. It is a foundational CRISPR-Cas patent, not a diagnostic-specific clearance. The patent is evidence of recorded claims, not proof of clinical performance, regulatory approval, or commercial viability. This distinction is important for moat analysis: a granted patent shows an assignee recorded claims with the USPTO, but it does not by itself demonstrate that a CRISPR diagnostic will achieve FDA clearance, reimbursement, or market adoption.

2.4 Regulator technical assessment: FDA LDT final rule

On May 6, 2024, the FDA published the final rule “Medical Devices; Laboratory Developed Tests,” Federal Register document 2024-08936 [S4]. The rule phases out the agency’s general enforcement discretion for laboratory-developed tests (LDTs) over multiple staged compliance dates, subjecting many LDTs to medical-device requirements including registration, listing, device reporting, labeling, design controls, and eventually premarket review for many tests [S4]. This is a Tier 1 regulator technical assessment because it is the primary rule text in the Federal Register.

Cross-reference against public-company filings

I reviewed the SEC filing pages or investor-relations SEC filing portals for Illumina [S5], Thermo Fisher [S6], Danaher [S7], Agilent [S8], QIAGEN [S9], Twist Bioscience [S10], Exact Sciences [S11], Guardant Health [S12], Bio-Rad [S13], and Pacific Biosciences [S14].

3.1 What filings disclose

• Illumina’s 10-K page [S5] contains annual reports disclosing that the company sells sequencing instruments, consumables, and services used in research and clinical applications, and that its business is subject to regulatory and reimbursement risk. Illumina’s filings do not report a separate CRISPR-diagnostic revenue segment [S5].
• Thermo Fisher’s 10-K page [S6] discloses a life-sciences portfolio that includes reagents, instruments, and consumables used in molecular biology and diagnostics. No standalone CRISPR-diagnostic IVD revenue line is visible in the linked SEC filing index [S6].
• Danaher’s 10-K page [S7] covers a diversified life-sciences and diagnostics portfolio. Danaher owns IDT, which sells CRISPR-Cas enzymes and custom oligonucleotides, and Cepheid, a molecular diagnostics business. The filing index does not show CRISPR-diagnostic revenue separated from the broader segments [S7].
• Twist Bioscience’s SEC filings [S10] disclose synthetic DNA products, including products used in CRISPR workflows. No CRISPR-diagnostic clinical clearance is presented as the central financial driver in the filing index [S10].
• Exact Sciences [S11], Guardant Health [S12], Agilent [S8], Bio-Rad [S13], and PacBio [S14] are material adjacent diagnostics/research-tool companies, but their SEC filing indexes also do not evidence a public-market CRISPR-diagnostic revenue segment.

3.2 Discrepancy statement

Technical papers [S1][S2] demonstrate high analytical sensitivity in laboratory conditions and describe portable/low-cost potential for CRISPR diagnostics. Public-company filings [S5–S14], however, discuss regulatory, reimbursement, and commercialization risk as ordinary-course risk factors, and none of the sampled public companies reports a distinct CRISPR-diagnostic IVD revenue line. Separately, the FDA LDT final rule [S4] now imposes medical-device controls on many laboratory-developed tests, which is a regulatory burden not present in the original CLIA-only LDT environment often assumed in early CRISPR-diagnostic deployment discussions. This is the main marketing-vs-filing discrepancy: technical feasibility is well-evidenced; commercialized, reimbursed, FDA-cleared CRISPR IVD revenue is not yet evidenced in public filings.

Quantitative worked calculation: attomolar limit of detection to copies per reaction

4.1 Formula

To convert a molar limit of detection (LOD) to copies of target per reaction:

\[

\text{copies} = C \times V \times N_A

\]

Where:

• \(C\) = concentration in mol/L
• \(V\) = reaction volume in liters
• \(N_A\) = Avogadro constant = \(6.02214076 \times 10^{23}\) mol\(^{-1}\) [S15]

4.2 Inputs

• Assumed LOD concentration: 1 attomolar (1 aM = \(1 \times 10^{-18}\) mol/L), a round-numbered value consistent with the attomolar-sensitivity language in the Tier 1 paper [S1].
• Reaction volume: 10 µL = \(1.0 \times 10^{-5}\) L.
• Avogadro constant: \(6.02214076 \times 10^{23}\) mol\(^{-1}\) [S15].

4.3 Calculation

\[

N = (1 \times 10^{-18}\ \text{mol/L}) \times (1.0 \times 10^{-5}\ \text{L}) \times (6.022 \times 10^{23}\ \text{mol}^{-1})

\]

\[

N = 6.022 \approx 6 \text{ copies per reaction}

\]

If the LOD were 2 aM instead of 1 aM:

\[

N = 2 \times 6.022 \approx 12 \text{ copies per reaction}

\]

4.4 Sensitivity interpretation

At 1 aM in 10 µL, the assay is operating at roughly six target copies per reaction. If the concentration drops to 0.1 aM, the expected copy count falls to about 0.6 copies per reaction, which is below the Poisson-limited single-molecule threshold. This explains why attomolar-class LODs are near the physical floor for bulk reactions, and why reduced input concentration or smaller reaction volume increases sampling uncertainty. This calculation is derived from an assumed LOD, not a primary measurement; the source paper supports “attomolar” sensitivity language but does not provide the exact 1 aM value as a universal cutoff for all targets [S1]. Exact target-specific LOD values need primary source validation.

4.5 Parameter table

Technology stack and value chain

5.1 Detection layer

The detection layer is the CRISPR-Cas effector plus a guide RNA and a reporter oligo. In SHERLOCK, Cas13a binds a target ssRNA and then cleaves a labeled reporter RNA, producing signal [S1]. In DETECTR, Cas12a binds target dsDNA and then cleaves labeled ssDNA reporters [S2]. These mechanisms are the core IP/performance layer.

5.2 Tool and reagent layer

Public life-science companies sell the tools needed to run the detection layer: custom guide RNAs and reporter oligos (Twist, IDT/Danaher), qPCR and plate-reader instruments (Thermo Fisher, Bio-Rad, Agilent, QIAGEN), and sequencing for orthogonal validation (Illumina, PacBio) [S5–S14]. This tool layer is where current public-market revenue is most visible.

5.3 Clinical translation layer

Once a CRISPR assay becomes a clinical test, it may be offered as an LDT, a distributed kit, or a point-of-care cartridge. The FDA LDT rule now regulates many LDTs as devices, with staged compliance dates [S4]. Clinical laboratories therefore become both buyers and regulated parties in this layer.

Unit economics / business model

6.1 Who monetizes this technology

• Private CRISPR-diagnostic developers propose sample-to-answer test kits, cartridge tests, or CLIA-lab services. Public financial data for these private entities is not available; margins require primary source validation.
• Public tool and reagent companies monetize through instrument sales/leases plus consumables pull-through, service contracts, and proprietary reagent kits [S5–S14]. This is the established model in research tools.
• Patent assignees monetize through licensing and running royalties, but the specific licensing structure of US8697359B2 is not detailed in the patent document itself; it is a recorded patent claim, not a license ledger [S3].

6.2 How the value is captured

Current evidence suggests value capture is more certain in the tool/reagent layer than in the clinical IVD layer. Public filings show revenue from life-science tools, consumables, and services [S5–S14], while CRISPR-specific clinical revenue is not separately disclosed. The clinical layer also carries FDA LDT regulatory cost and delay risk [S4], and reimbursement risk is a standard risk factor in public diagnostics filings [S5][S7][S11][S12].

6.3 Margin disclosure

No reliable CRISPR-diagnostic segment margin figure was located in the sources assembled here. Public life-science tool companies report gross margins, but segment-level margins attributable specifically to CRISPR diagnostics are not disclosed. Any margin estimate should be marked needs primary source validation.

Disconfirming Evidence

The thesis that CRISPR-based diagnostics and adjacent research tools are a durable commercial opportunity would be materially weakened if any of the following occurs:

1. Independent clinical validation fails. If multisite trials show that Cas13/Cas12 assays have lower clinical sensitivity or specificity than RT-qPCR or existing molecular diagnostics, the Tier 1 laboratory advantage does not translate.
2. FDA denies or extensively delays premarket submissions. The LDT final rule [S4] creates deadlines; if CRISPR-based tests cannot meet performance or quality-system requirements, clinical translation stalls.
3. Payors decline coverage or price at commodity levels. If clinical laboratories cannot obtain reimbursement for novel CRISPR assays, the diagnostic-kit layer will remain economically unattractive even if technical performance is strong.
4. Public reagent sales remain immaterial. If public companies’ CRISPR-related product lines remain too small to disclose, the tool-layer value capture thesis is not confirmed.
5. Patent claims are invalidated or narrowed. A granted patent [S3] is challenged in interference, post-grant review, or litigation; if key claims are canceled, the IP moat weakens.
6. Alternative diagnostics win on cost or throughput. If high-multiplex qPCR, isothermal amplification, antigen, or sequencing-based approaches deliver equivalent clinical utility at lower regulatory burden, CRISPR diagnostics may remain niche.